Kragballe K, Steijlen P M, Ibsen H H, van de Kerkhof P C, Esmann J, Sorensen L H, Axelsen M B
Department of Dermatology, University Hospital Aarhus, Denmark.
Arch Dermatol. 1995 May;131(5):556-60.
Disorders of keratinization are a heterogeneous group of diseases that have in common a defect in cornification. The bioactive form of vitamin D3 has been shown to modulate epidermal proliferation and differentiation. The purpose of the present study was to determine the effect of the synthetic vitamin D3 calcipotriol in a randomized, double-blind, placebo-controlled, right/left comparative study. The 67 patients included in the study were at least 12 years of age and had the following diseases: ichthyosis vulgaris (n = 9), X-linked ichthyosis (n = 8), congenital ichthyosis (n = 10), hereditary palmoplantar keratoderma (n = 20), keratosis pilaris (n = 9), and Darier's disease (n = 11). Calcipotriol ointment (50 micrograms/g) and placebo (vehicle of calcipotriol ointment) were applied to all patients twice daily for up to 12 weeks. The patients were allowed to use up to 120 g of calcipotriol ointment per week.
At the end of the treatment regimen, calcipotriol ointment had an effect on the improvement of the ichthyoses, although to a variable degree. No therapeutic effect was detected in palmoplantar keratoderma or keratosis pilaris. Eight of 12 patients with Darier's disease had to be withdrawn because of skin irritation or a worsening of the disease. Skin irritation occurred in 18 cases (26%) only on the calcipotriol-treated side, and in one case (1%) only on the placebo-treated side. Nine cases (13%) had irritation on both sides. The amount of calcipotriol ointment used per week was lowest in palmoplantar keratoderma (mean, 11.8 g/wk; range, 2.1 to 25.6 g/wk) and highest in congenital ichthyosis (mean, 59.3 g/wk; range, 11.4 to 94.7 g/wk). There was no clinically significant change of serum calcium levels during the treatment period.
Short-term treatment with calcipotriol ointment (50 micrograms/g) used in amounts up to about 100 g/wk is moderately efficacious, well-tolerated, and safe in adult patients with various ichthyoses.
角化异常是一组异质性疾病,其共同特征是角质化存在缺陷。维生素D3的生物活性形式已被证明可调节表皮增殖和分化。本研究的目的是在一项随机、双盲、安慰剂对照、左右对比研究中确定合成维生素D3卡泊三醇的效果。纳入研究的67例患者年龄至少12岁,患有以下疾病:寻常型鱼鳞病(n = 9)、X连锁鱼鳞病(n = 8)、先天性鱼鳞病(n = 10)、遗传性掌跖角化病(n = 20)、毛发角化病(n = 9)和 Darier病(n = 11)。卡泊三醇软膏(50微克/克)和安慰剂(卡泊三醇软膏基质)每天两次涂抹于所有患者,持续12周。患者每周最多可使用120克卡泊三醇软膏。
在治疗方案结束时,卡泊三醇软膏对角化病的改善有效果,尽管程度不同。在掌跖角化病或毛发角化病中未检测到治疗效果。12例Darier病患者中有8例因皮肤刺激或病情恶化而退出。皮肤刺激仅发生在卡泊三醇治疗侧的有18例(26%),仅发生在安慰剂治疗侧的有1例(1%)。双侧都有刺激的有9例(13%)。每周使用的卡泊三醇软膏量在掌跖角化病中最低(平均,11.8克/周;范围,2.1至25.6克/周),在先天性鱼鳞病中最高(平均,59.3克/周;范围,11.4至94.7克/周)。治疗期间血清钙水平无临床显著变化。
对于患有各种鱼鳞病的成年患者,每周使用量达约100克的50微克/克卡泊三醇软膏进行短期治疗具有中等疗效,耐受性良好且安全。